Phase 2 Leukaemia Trial, Recruiting (NCT05881265)

Phase 2 Leukaemia Trial, Recruiting NCT05881265 Sponsor: Shanghai Jiao Tong University School of Medicine Condition: Leukaemia

Printed from Voxsanity (voxsanity.com.au) — NCT05881265 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Leukaemia

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People diagnosed with a specific type of acute leukaemia called APL that has a particular genetic marker (PML-RARα+)
People whose leukaemia has not gone into remission after receiving a standard treatment combination of retinoic acid and arsenic
People with a life expectancy of 3 months or more
People who have given their informed consent to participate

Who may not be able to join:

People who have an infection that cannot be controlled or managed
People with a life expectancy of less than 2 months
People whose liver or kidney function test results are significantly abnormal — specifically, more than 3 times above the normal range (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Chun Wang, Zhaxin Hospital, Go Broad Health Care

Phone: 8613386259777

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05881265

Sponsor: Shanghai Jiao Tong University School of Medicine

Phase: Phase 2

Status: Recruiting

Condition: Leukaemia

Trial contact: 8613386259777

More information: https://clinicaltrials.gov/study/NCT05881265

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People diagnosed with a specific type of acute leukaemia called APL that has a particular genetic marker (PML-RARα+)
People whose leukaemia has not gone into remission after receiving a standard treatment combination of retinoic acid and arsenic
People with a life expectancy of 3 months or more
People who have given their informed consent to participate

Who may not be able to join:

People who have an infection that cannot be controlled or managed
People with a life expectancy of less than 2 months
People whose liver or kidney function test results are significantly abnormal — specifically, more than 3 times above the normal range (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Shanghai Jiao Tong University School of Medicine

Registry

ClinicalTrials.gov

Start date

15 May 2023

Est. completion

1 January 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

complete remission and complete remission with incomplete recovery of peripheral blood count

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov